REMYND
Their Contract Research Organization (CRO) helps their clients assess the effects of their experimental Alzheimer treatments in their proprietary mouse models. They serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. They have provided pivotal in-vivo proof-of-concept data for several candidate drugs currently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept.
REMYND
Industry:
Biotechnology
Founded:
2012-01-01
Address:
Leuven, Vlaams-Brabant, Belgium
Country:
Belgium
Website Url:
http://www.remynd.com
Total Employee:
51+
Status:
Active
Contact:
+32 16 75 14 20
Email Addresses:
[email protected]
Total Funding:
24 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Content Delivery Network Google Universal Analytics Font Awesome Apache Amazon
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Impact Biomedicines
Impact Biomedicines is pioneering the development of life-changing treatments for patients.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Advisors List
Current Employees Featured
Founder
Investors List
PMV
PMV investment in Series B - reMYND
FPIM
FPIM investment in Series B - reMYND
University of Leuven
University of Leuven investment in Series B - reMYND
Korys
Korys investment in Series B - reMYND
BNP Paribas Fortis
BNP Paribas Fortis investment in Series B - reMYND
Gemma Frisius Fund
Gemma Frisius Fund investment in Series B - reMYND
Korys
Korys investment in Series B - reMYND
University of Leuven
University of Leuven investment in Series B - reMYND
BNP Paribas Fortis
BNP Paribas Fortis investment in Series B - reMYND
PMV
PMV investment in Series B - reMYND
Official Site Inspections
http://www.remynd.com Semrush global rank: 5.77 M Semrush visits lastest month: 1.45 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "reMYND"
reMYND | Driving the development of disease-modifying treatments
Our Contract Research Organization (CRO) helps our clients assess the effects of their experimental Alzheimer and other neurodegenerative disease treatments in our proprietary …See details»
About us - reMYND
ReMYND is a biotech company developing treatments for Alzheimer’s, Huntington's and other diseases caused by cellular dysfunction. It is backed …See details»
reMYND and the US NINDS Epilepsy Therapy Screening Program …
Nov 4, 2021 · reMYND is a clinical stage company developing novel treatments for Alzheimer’s, diabetes, epilepsy and other diseases caused by cellular dysfunction. It is backed by a …See details»
reMYND Company Profile 2024: Valuation, Funding
The company is a contract research organization (CRO) with extensive experience in the testing of experimental Alzheimer therapies in its proprietary transgenic mouse models and actively drives research and development in …See details»
reMYND - Crunchbase Company Profile & Funding
ReMYND drives the development of disease-modifying treatments against protein misfolding disorders. View contacts for reMYND to access new leads and connect with decision-makers. Their Contract Research Organization (CRO) helps …See details»
reMYND and the US NINDS Epilepsy Therapy Screening Program
Nov 4, 2021 · reMYND is a clinical stage company developing novel treatments for Alzheimer’s, diabetes, epilepsy and other diseases caused by cellular dysfunction. It is backed by a …See details»
reMYND commences first-in-human trial of ReS19 ... - Associated …
Dec 3, 2020 · reMYND is a clinical stage company developing treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction. It is backed by a proprietary drug …See details»
reMYND announces publication in Science of novel drug target …
May 30, 2024 · reMYND NV, a biotech company tackling neurodegeneration, is pleased to announce the publication in the prestigious journal Science of research detailing the …See details»
reMYND’s ReS19-T program, managing calcium homeostasis for
Oct 21, 2021 · reMYND is a clinical stage company developing novel treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction. It is backed by a proprietary drug …See details»
Corporate - reMYND
Leuven Belgium, 03 May 2022: reMYND NV, a clinical stage company tackling neurodegeneration, today announces that its lead Alzheimer program ReS19-T has …See details»
reMYND commences first-in-human trial of ReS19-T Alzheimer’s …
Dec 3, 2020 · reMYND is a clinical stage company developing treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction. It is backed by a proprietary drug …See details»
reMYND | Alzheimer's Drug Discovery Foundation
Thus, treatments which restore the normal levels and action of calcium in the diseased neurons of AD patients have a promising therapeutic potential. reMYND has discovered a novel candidate …See details»
reMYND’s ReS19-T program, managing calcium homeostasis for …
Oct 21, 2021 · reMYND is a clinical stage company developing novel treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction. It is backed by a proprietary drug …See details»
reMYND announces publication in Science of novel drug target …
May 30, 2024 · reMYND is a company developing novel treatments for Alzheimer’s, Huntington’s, epilepsy, ALS and other neurodegenerative diseases caused by neuronal dysfunction. It is …See details»
reMYND commences first-in-human trial of ReS19-T
Dec 3, 2020 · reMYND is a clinical stage company developing treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction. It is backed by a proprietary drug …See details»
reMYND extends Series B funding to EUR 24 million
Jan 21, 2021 · reMYND is a clinical stage company developing novel treatments for Alzheimer’s, diabetes and other diseases caused by cellular dysfunction. It is backed by a proprietary drug …See details»
reMYND’s ReS19-T program, managing calcium homeostasis for …
Oct 21, 2021 · reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phaseSee details»
reMYND’s novel Alzheimer program reports excellent brain …
Leuven Belgium, 03 May 2022: reMYND NV, a clinical stage company tackling neurodegeneration, today announces that its lead Alzheimer program ReS19-T has …See details»
Pharmacological modulation of septins restores calcium …
To overcome this challenge, we set out to identify calcium influx pathways excessively activated in pathological conditions and developed a cell-based model of tau toxicity that strictly depends …See details»
reMYND’s novel Alzheimer program reports excellent brain
Leuven Belgium, 03 May 2022: reMYND NV, a clinical stage company tackling neurodegeneration, today announces that its lead Alzheimer program ReS19-T has …See details»